Comparative Efficacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis
Oral Mucositis
About this trial
This is an interventional prevention trial for Oral Mucositis
Eligibility Criteria
Inclusion Criteria:Male and female patients with head and neck cancer and who will be prescribed radiotherapy at least 60 Gy (Roopashri et al., 2011).
- Patients who will sign an informed consent,
- Patients older than 18 years of age,
- Patients having normal renal and liver functions
Exclusion Criteria:• . Use of dentures, or having any source of infection in the mouth.
- Allergy to rebamipide or benzydamine hydrochloride(Nithin et al., 2018) .
Sites / Locations
- Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Benzydamine hydrochloride
Rebamipide
group I ( benzdymine HCL ); subject will be instructed to use Benzydamine hydrochloride gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ). dose :5 ml every time dosage form ; mouth wash
group II ( rebamipide) :subject will be instructed to use Rebamipide gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ). dosage form ; mouth wash